Chemotherapy Adverse Events

About NETRI

NETRI is a pioneering organ-on-a-chip company based in Lyon, France, that has developed a proprietary, compartmentalized microelectrode array (MEA) platform in a 96-well format for high-throughput electrophysiological recording of neuronal networks. The company's core value proposition is providing pharmaceutical and dermocosmetic companies with highly predictive human-relevant data on neurotoxicity, chemotherapy-induced peripheral neuropathy, and immunogenicity, aiming to reduce clinical failures and animal testing. By combining its patented microfluidic devices with a growing Digital Signature Library of compound profiles analyzed by AI, NETRI positions itself as a key enabler for faster, cheaper, and more ethical drug development. The company operates as a B2B platform and services provider, manufacturing its devices in-house while collaborating with large pharmaceutical partners.

Therapeutic Areas

Other Chemotherapy-Induced Peripheral Neuropathy (CIPN) Drugs